Provided by Tiger Fintech (Singapore) Pte. Ltd.

BioCardia

1.73
-0.0528-2.97%
Volume:15.78K
Turnover:27.99K
Market Cap:8.08M
PE:-0.60
High:1.84
Open:1.84
Low:1.73
Close:1.78
Loading ...

Press Release: BioCardia Reports 2024 Business Highlights and Financial Results

Dow Jones
·
27 Mar

BioCardia Inc expected to post a loss of 62 cents a share - Earnings Preview

Reuters
·
25 Mar

BioCardia Inc expected to post a loss of 62 cents a share - Earnings Preview

Reuters
·
21 Mar

BioCardia Gets Patent in Japan for Helix Biotherapeutic Delivery System

MT Newswires Live
·
11 Mar

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

GlobeNewswire
·
10 Mar

Director’s Bold Move: Major Stock Purchase Signals Confidence in BioCardia

TIPRANKS
·
06 Mar

BioCardia finishes data freezing in heart failure therapy study for presentation

TIPRANKS
·
27 Feb

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

GlobeNewswire
·
27 Feb

BRIEF-BioCardia Reports Completion Of Low Dose Cohort Enrollment For Cardiallo Phase I/II Clinical Trial

Reuters
·
13 Feb

BioCardia Reports Completion of Low Dose Cohort Enrollment for Cardiallo Phase I/Ii Clinical Trial of Bcda-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (Hfref)

THOMSON REUTERS
·
13 Feb

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

GlobeNewswire
·
13 Feb

BioCardia upgraded to Buy from Neutral at Alliance Global Partners

TipRanks
·
31 Jan

BioCardia Inc : Alliance Global Partners Raises to Buy From Neutral

THOMSON REUTERS
·
30 Jan

BioCardia Announces Late Breaking Clinical Trial Presentation on Cardiamp Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

THOMSON REUTERS
·
27 Jan

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

GlobeNewswire
·
27 Jan

BioCardia Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Dec 2024

Positive Outlook on BioCardia: Strategic Growth and Regulatory Advancements Drive Buy Rating

TIPRANKS
·
18 Dec 2024

BRIEF-Biocardia Announces Commercial Availability Of Morph® Dna™ Steerable Introducer Product Family

Reuters
·
17 Dec 2024

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

THOMSON REUTERS
·
17 Dec 2024

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

GlobeNewswire
·
17 Dec 2024